US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nuvectis Pharma, Inc.

8.87

+0.16501.90%

Post-market: 8.870.00000.00%16:00 EDT

Volume:125.60K

Turnover:1.12M

Market Cap:207.37M

PE:-7.98

High:9.30

Open:8.86

Low:8.78

Close:8.70

Loading ...

Overview Company News Filings

Nuvectis Pharma Initiated at Buy by Maxim Group

Maxim Initiates Nuvectis Pharma at Buy With $17 Price Target

MT Newswires Live

Nuvectis Pharma Inc : Maxim Group Initiates Coverage With Buy Rating; Price Target $17

THOMSON REUTERS

Nuvectis Pharma Announces Upcoming Presentations for Nxp900 at the 2025 American Association for Cancer Research Meeting

THOMSON REUTERS

Nuvectis Pharma to Participate in the 37th Annual Roth Conference

Market News Alert: Nuvectis Pharma’s NXP900 Demonstrates Superior Efficacy in NSCLC When Combined with Tagrisso in Cleveland Clinic Study, Following New Buy Recommendation

Nuvectis Pharma Announces a New Publication of a Research Study Demonstrating that the Combination of NXP900 and EGFR Inhibitors Improves the Efficacy of the EGFR Inhibitors in Preclinical Models of EGFR Mutated NSCLC

Market News Alert: Nuvectis Pharma Receives $18 Price Target and Buy Rating from Lucid Capital Markets

Nuvectis Pharma Is Maintained at Buy by HC Wainwright & Co.

Optimistic Buy Rating for Nuvectis Pharma Driven by Promising Oncology Pipeline and Strong Financial Position

Nuvectis Pharma price target lowered to $11 from $21 at H.C. Wainwright

Nuvectis Pharma, Inc. : H.c. Wainwright Cuts Target Price to $11 From $21

THOMSON REUTERS

Nuvectis Pharma 2024 Net Loss $19M

Nuvectis Pharma reports FY24 EPS ($1.11) vs. ($1.43) last year

Nuvectis Pharma, Inc. Reports 2024 Financial Results and Business Highlights

Major Investment Alert: Shareholder’s Big Move in Nuvectis Pharma!

Nuvectis Pharma Closes Stock Offering, Says Underwriter Exercised Overallotment Option

MT Newswires Live

Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter’s Over-Allotment Option

THOMSON REUTERS

Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter’s Over-Allotment Option

Nuvectis Pharma Prices $13.5 Million Public Offering of Shares

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NVCT/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NVCT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVCT\",,,,,undefined,":{"symbol":"NVCT","market":"US","secType":"STK","nameCN":"Nuvectis Pharma, Inc.","latestPrice":8.865,"timestamp":1744920000000,"preClose":8.7,"halted":0,"volume":125600,"hourTrading":{"tag":"盘后","latestPrice":8.865,"preClose":8.865,"latestTime":"16:00 EDT","volume":84,"amount":744.66,"timestamp":1744920008213},"delay":0,"floatShares":12768280,"shares":23391499,"eps":-1.110256,"marketStatus":"Closed Good Friday","change":0.165,"latestTime":"04-17 16:00:00 EDT","open":8.86,"high":9.3,"low":8.78,"amount":1124042.4159,"amplitude":0.05977,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.110256,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"listingDate":1638334800000,"exchange":"NASDAQ","adjPreClose":8.7,"preHourTrading":{"tag":"盘前","latestPrice":8.7,"preClose":8.7,"latestTime":"07:39 EDT","volume":202,"amount":1708.700022,"timestamp":1744889964559},"postHourTrading":{"tag":"盘后","latestPrice":8.865,"preClose":8.865,"latestTime":"16:00 EDT","volume":84,"amount":744.66,"timestamp":1744920008213},"volumeRatio":1.088397645672217,"impliedVol":2.0072,"impliedVolPercentile":0.8537},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVCT\",,,,,undefined,":{"symbol":"NVCT","floatShares":12768280,"roa":"-65.65%","roe":"-173.41%","lyrEps":-1.110256,"volumeRatio":1.088397645672217,"shares":23391499,"dividePrice":0,"high":9.3,"amplitude":0.05977,"preClose":8.7,"low":8.78,"week52Low":4.44,"pbRate":"21.35","week52High":11.8,"institutionHeld":0,"latestPrice":8.865,"eps":-1.110256,"divideRate":0,"volume":125600,"delay":0,"ttmEps":-1.110256,"open":8.86,"prevYearClose":5.41,"prevWeekClose":8.31,"prevMonthClose":9.77,"prevQuarterClose":9.77,"fiveDayClose":8.525,"twentyDayClose":9.35,"sixtyDayClose":6.1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVCT\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2524145754","title":"Nuvectis Pharma Initiated at Buy by Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2524145754","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524145754?lang=en_us&edition=fundamental","pubTime":"2025-04-03 01:24","pubTimestamp":1743614640,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NVCT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 02, 2025 13:24 ET (17:24 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NVCT"],"gpt_icon":0},{"id":"2524182934","title":"Maxim Initiates Nuvectis Pharma at Buy With $17 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2524182934","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524182934?lang=en_us&edition=fundamental","pubTime":"2025-04-02 23:26","pubTimestamp":1743607606,"startTime":"0","endTime":"0","summary":"Nuvectis Pharma (NVCT) has an average rating of buy and mean price target of $17, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NVCT"],"gpt_icon":0},{"id":"2524464653","title":"Nuvectis Pharma Inc : Maxim Group Initiates Coverage With Buy Rating; Price Target $17","url":"https://stock-news.laohu8.com/highlight/detail?id=2524464653","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524464653?lang=en_us&edition=fundamental","pubTime":"2025-04-02 19:42","pubTimestamp":1743594173,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250402:nFWN3QG0W3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NVCT","BK4139"],"gpt_icon":0},{"id":"2522871081","title":"Nuvectis Pharma Announces Upcoming Presentations for Nxp900 at the 2025 American Association for Cancer Research Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2522871081","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522871081?lang=en_us&edition=fundamental","pubTime":"2025-03-26 20:00","pubTimestamp":1742990403,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nTUA7MMRWB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NVCT"],"gpt_icon":0},{"id":"2519809873","title":"Nuvectis Pharma to Participate in the 37th Annual Roth Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2519809873","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519809873?lang=en_us&edition=fundamental","pubTime":"2025-03-14 20:00","pubTimestamp":1741953600,"startTime":"0","endTime":"0","summary":"Ron Bentsur Chairman, Chief Executive Officer and President  rbentsur@nuvectis.com","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nuvectis-pharma-participate-37th-annual-120000149.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","NVCT"],"gpt_icon":0},{"id":"2517691282","title":"Market News Alert: Nuvectis Pharma’s NXP900 Demonstrates Superior Efficacy in NSCLC When Combined with Tagrisso in Cleveland Clinic Study, Following New Buy Recommendation","url":"https://stock-news.laohu8.com/highlight/detail?id=2517691282","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517691282?lang=en_us&edition=fundamental","pubTime":"2025-03-05 21:44","pubTimestamp":1741182240,"startTime":"0","endTime":"0","summary":"Cleveland Clinic research provides further positive validation Nuvectis Pharma's* NXP900 cancer-fighting potential, showing enhanced efficacy when combined with AstraZeneca's blockbuster drug Tagrisso in EGFR+ lung cancer models. New $18 price target and buy recommendation from Lucid Capital Markets implies 200%+ potential upside as Phase 1b trial approaches. NEW YORK, March 05, 2025----Market News Alerts Reports: Nuvectis Pharma * announced today that new independent research conducted at the Lerner Research Institute, Cleveland Clinic  has demonstrated the superior efficacy of NXP900 when combined with osimertinib  in EGFR-mutated non-small cell lung cancer  models. The peer-reviewed study, published in Molecular Cancer Research, demonstrated that the combination therapy led to decreased cancer cell proliferation and increased apoptosis compared to osimertinib alone.Nuvectis Pharma Announces a New Publication of a Research Study Demonstrating that the Combination of NXP900 and EGFR I","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/market-news-alert-nuvectis-pharma-134400714.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Market News Alert: Nuvectis Pharma’s NXP900 Demonstrates Superior Efficacy in NSCLC When Combined with Tagrisso in Cleveland Clinic Study, Following New Buy Recommendation","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","NVCT"],"gpt_icon":0},{"id":"2516757996","title":"Nuvectis Pharma Announces a New Publication of a Research Study Demonstrating that the Combination of NXP900 and EGFR Inhibitors Improves the Efficacy of the EGFR Inhibitors in Preclinical Models of EGFR Mutated NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2516757996","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516757996?lang=en_us&edition=fundamental","pubTime":"2025-03-04 21:00","pubTimestamp":1741093200,"startTime":"0","endTime":"0","summary":"Research conducted at the Lerner Research Institute, Cleveland Clinic . Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, “As we continue our activities toward the initiation of the Phase 1b program of NXP900, we are very pleased to see yet another independently generated dataset from a highly reputable research institution demonstrating the synergistic effect of adding NXP900 to osimertinib in EGFR mutated NSCLC. With the Phase 1a dose escalation study nearing completion, we are excited about the potential opportunities presented by NXP900 in therapeutic areas of unmet medical need, both as a single agent and in combination with market-leading anti-cancer drugs.”","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nuvectis-pharma-announces-publication-research-130000051.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NVCT"],"gpt_icon":0},{"id":"2514087382","title":"Market News Alert: Nuvectis Pharma Receives $18 Price Target and Buy Rating from Lucid Capital Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2514087382","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514087382?lang=en_us&edition=fundamental","pubTime":"2025-02-27 23:43","pubTimestamp":1740670980,"startTime":"0","endTime":"0","summary":"Precision oncology player Nuvectis Pharma receives a buy recommendation and price target with a significant premium from Lucid Capital Markets. Report highlights Nuvectis’ potential to generate hundreds of millions of dollars in revenue and notes upcoming phase 1a clinical data as a potential catalyst. NEW YORK, February 27, 2025----Market News Alerts Reports: Lucid Capital Markets has initiated coverage on Nuvectis Pharma  with a Buy rating and a price target of $18. The firm's report highlights Nuvectis' promising oncology pipeline, particularly its lead asset, NXP900, a SRC/YES1 inhibitor targeting squamous cell carcinomas with high unmet need.Lucid's report emphasizes the strong potential of NXP900, which is currently in Phase 1 clinical trials and has shown an encouraging safety profile while continuing dose escalation. The firm projects peak non-risk-adjusted sales of over $900 million for NXP900 across multiple cancer indications by 2041.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/market-news-alert-nuvectis-pharma-154300160.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NVCT"],"gpt_icon":1},{"id":"2514014665","title":"Nuvectis Pharma Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2514014665","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514014665?lang=en_us&edition=fundamental","pubTime":"2025-02-26 00:57","pubTimestamp":1740502620,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NVCT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 25, 2025 11:57 ET (16:57 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCT"],"gpt_icon":0},{"id":"2514203014","title":"Optimistic Buy Rating for Nuvectis Pharma Driven by Promising Oncology Pipeline and Strong Financial Position","url":"https://stock-news.laohu8.com/highlight/detail?id=2514203014","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514203014?lang=en_us&edition=fundamental","pubTime":"2025-02-26 00:45","pubTimestamp":1740501915,"startTime":"0","endTime":"0","summary":"Joseph Pantginis, an analyst from H.C. Wainwright, maintained the Buy rating on Nuvectis Pharma (NVCT – Research Report). The associated price targ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/optimistic-buy-rating-for-nuvectis-pharma-driven-by-promising-oncology-pipeline-and-strong-financial-position?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/optimistic-buy-rating-for-nuvectis-pharma-driven-by-promising-oncology-pipeline-and-strong-financial-position?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVCT"],"gpt_icon":0},{"id":"2514011041","title":"Nuvectis Pharma price target lowered to $11 from $21 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2514011041","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514011041?lang=en_us&edition=fundamental","pubTime":"2025-02-26 00:37","pubTimestamp":1740501428,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Joseph Pantginis lowered the firm’s price target on Nuvectis Pharma (NVCT) to $11 from $21 and keeps a Buy rating on the sh...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nuvectis-pharma-price-target-lowered-to-11-from-21-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nuvectis-pharma-price-target-lowered-to-11-from-21-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVCT"],"gpt_icon":0},{"id":"2514011564","title":"Nuvectis Pharma, Inc. : H.c. Wainwright Cuts Target Price to $11 From $21","url":"https://stock-news.laohu8.com/highlight/detail?id=2514011564","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514011564?lang=en_us&edition=fundamental","pubTime":"2025-02-26 00:27","pubTimestamp":1740500837,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nAZN3FXL33:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NVCT"],"gpt_icon":0},{"id":"2514809925","title":"Nuvectis Pharma 2024 Net Loss $19M","url":"https://stock-news.laohu8.com/highlight/detail?id=2514809925","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514809925?lang=en_us&edition=fundamental","pubTime":"2025-02-25 21:17","pubTimestamp":1740489445,"startTime":"0","endTime":"0","summary":"Nuvectis Pharma 2024 Net Loss $19M","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/02/43938609/nuvectis-pharma-2024-net-loss-19m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NVCT"],"gpt_icon":0},{"id":"2514995750","title":"Nuvectis Pharma reports FY24 EPS ($1.11) vs. ($1.43) last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2514995750","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514995750?lang=en_us&edition=fundamental","pubTime":"2025-02-25 21:06","pubTimestamp":1740488810,"startTime":"0","endTime":"0","summary":"Ron Bentsur, CEO commented, “In 2024, Nuvectis made important progress in the development of our two clinical-stage drug candidates, NXP800 and NXP...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nuvectis-pharma-reports-fy24-eps-1-11-vs-1-43-last-year?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nuvectis-pharma-reports-fy24-eps-1-11-vs-1-43-last-year?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVCT"],"gpt_icon":0},{"id":"2514009995","title":"Nuvectis Pharma, Inc. Reports 2024 Financial Results and Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2514009995","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514009995?lang=en_us&edition=fundamental","pubTime":"2025-02-25 21:00","pubTimestamp":1740488400,"startTime":"0","endTime":"0","summary":"NXP800 Phase 1b study in patients with platinum resistant, ARID1a-mutated ovarian cancer is ongoing; Orphan Drug Designation granted by the U.S. FDA. Updated Phase 1b results anticipated in Q2 2025NXP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/25/3031964/0/en/Nuvectis-Pharma-Inc-Reports-2024-Financial-Results-and-Business-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NVCT"],"gpt_icon":0},{"id":"2510399871","title":"Major Investment Alert: Shareholder’s Big Move in Nuvectis Pharma!","url":"https://stock-news.laohu8.com/highlight/detail?id=2510399871","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510399871?lang=en_us&edition=fundamental","pubTime":"2025-02-12 10:02","pubTimestamp":1739325726,"startTime":"0","endTime":"0","summary":"New insider activity at Nuvectis Pharma ( ($NVCT) ) has taken place on February 12, 2025. Significant shareholder Marlio Charles Mosseri has made a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/major-investment-alert-shareholders-big-move-in-nuvectis-pharma?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/major-investment-alert-shareholders-big-move-in-nuvectis-pharma?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVCT","BK4139"],"gpt_icon":0},{"id":"2509774436","title":"Nuvectis Pharma Closes Stock Offering, Says Underwriter Exercised Overallotment Option","url":"https://stock-news.laohu8.com/highlight/detail?id=2509774436","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509774436?lang=en_us&edition=fundamental","pubTime":"2025-02-07 22:37","pubTimestamp":1738939072,"startTime":"0","endTime":"0","summary":"Nuvectis Pharma  said Friday it closed its public offering of 2.7 million shares, with the underwriter exercising in full the option to buy 405,000 additional shares at $5 per share, boosting gross proceeds to about $15.5 million.The company said it expects to use the net proceeds from the offering to continue clinical development of its NXP800 and NXP900 product candidates, hire additional personnel, and for capital expenditures and other general corporate purposes.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","NVCT"],"gpt_icon":0},{"id":"2509745195","title":"Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter’s Over-Allotment Option","url":"https://stock-news.laohu8.com/highlight/detail?id=2509745195","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509745195?lang=en_us&edition=fundamental","pubTime":"2025-02-07 21:30","pubTimestamp":1738935000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250207:nTUA3PZM9X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NVCT"],"gpt_icon":0},{"id":"2509746550","title":"Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter’s Over-Allotment Option","url":"https://stock-news.laohu8.com/highlight/detail?id=2509746550","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509746550?lang=en_us&edition=fundamental","pubTime":"2025-02-07 21:30","pubTimestamp":1738935000,"startTime":"0","endTime":"0","summary":"FORT LEE, NJ, Feb. 07, 2025  -- Nuvectis Pharma, Inc. , a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the closing of its previously announced underwritten public offering of 2,700,000 shares of its common stock, and the exercise in full of the underwriter’s option to purchase 405,000 additional shares. The common stock shares were offered at a price of $5.00 per share, resulting in gross proceeds to Nuvectis of approximately $15.5 million, before deducting underwriting discounts and commissions.Lucid Capital Markets acted as the sole book runner for the offering.This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nuvectis-pharma-announces-closing-15-133000857.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NVCT","BK4139"],"gpt_icon":0},{"id":"2509332512","title":"Nuvectis Pharma Prices $13.5 Million Public Offering of Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2509332512","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509332512?lang=en_us&edition=fundamental","pubTime":"2025-02-05 23:51","pubTimestamp":1738770665,"startTime":"0","endTime":"0","summary":"Nuvectis Pharma  said Wednesday it has priced an underwritten public offering of 2.7 million of its shares at $5.00 apiece to raise $13.5 million.Nuvectis said it has also granted its underwriter a 30-day option to buy up to 405,000 additional shares. It expects to close the offering Feb. 6, with Lucid Capital Markets as the book runner.The proceeds will be used among others to advance its development programs, for capital expenditures, and other general corporate purposes, the clinical-stage company said.The shares were up over 6% in recent trading.Price: 7.48, Change: +0.48, Percent Change: +6.86","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NVCT","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":53,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVCT\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-02-25","symbol":"NVCT","fiscalQuarterEnding":"2024/12","expectedEps":-0.28,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1740459600000,"reportTimeType":"pre","actualEps":-0.36},{"market":"US","date":"2024-11-05","symbol":"NVCT","fiscalQuarterEnding":"2024/09","expectedEps":-0.26,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1730782800000,"reportTimeType":"pre","actualEps":-0.24},{"market":"US","date":"2024-08-06","symbol":"NVCT","fiscalQuarterEnding":"2024/06","expectedEps":-0.26,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1722916800000,"reportTimeType":"pre","actualEps":-0.26},{"market":"US","date":"2024-05-07","symbol":"NVCT","fiscalQuarterEnding":"2024/03","expectedEps":-0.4,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715054400000,"reportTimeType":"pre","actualEps":-0.25},{"market":"US","date":"2024-03-05","symbol":"NVCT","fiscalQuarterEnding":"2023/12","expectedEps":-0.4,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1709614800000,"reportTimeType":"pre","actualEps":-0.41}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVCT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVCT\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1667,"buy":0.8333,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8333,"analysts":6,"updateTime":1743652800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NVCT\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NVCT","date":"2025-04-17","current":-10.710844,"percent":0.236057,"low":-4822.163542,"twenty":-11.149702,"median":-7.758662,"eighty":-5.855152,"high":-4.507629,"avg":-160.683118,"sd":733.58844,"marketCap":203506041},"quantilePoints":[{"date":"2022-02-04","current":-1722.20125,"twenty":-2416.901458,"median":-2416.901458,"eighty":-2000.081333,"marketCap":41332830},{"date":"2022-02-11","current":-3677.562083,"twenty":-3582.178633,"median":-3306.626438,"eighty":-2416.901458,"marketCap":88261490},{"date":"2022-02-18","current":-3105.261333,"twenty":-3521.769108,"median":-3195.345708,"eighty":-2596.861958,"marketCap":74526272},{"date":"2022-02-25","current":-3359.617208,"twenty":-3425.325841,"median":-3227.140208,"eighty":-2883.759766,"marketCap":80630813},{"date":"2022-03-04","current":-3990.207833,"twenty":-3634.109608,"median":-3354.318146,"eighty":-2982.322667,"marketCap":95764988},{"date":"2022-03-11","current":-4382.339833,"twenty":-4096.189467,"median":-3439.103458,"eighty":-3123.278208,"marketCap":105176156},{"date":"2022-03-18","current":-4149.180292,"twenty":-4143.881209,"median":-3592.776792,"eighty":-3195.345708,"marketCap":99580327},{"date":"2022-03-25","current":-7.409669,"twenty":-4111.026892,"median":-3439.103458,"eighty":-2883.759766,"marketCap":95510632},{"date":"2022-04-01","current":-6.926215,"twenty":-4060.1557,"median":-3354.318146,"eighty":-350.415344,"marketCap":89278913},{"date":"2022-04-08","current":-9.323751,"twenty":-4037.899584,"median":-3227.140208,"eighty":-8.266073,"marketCap":120183153},{"date":"2022-04-14","current":-9.965067,"twenty":-4016.70325,"median":-3195.345708,"eighty":-8.337111,"marketCap":128449719},{"date":"2022-04-22","current":-9.550678,"twenty":-3990.207833,"median":-3028.424667,"eighty":-9.234954,"marketCap":123108245},{"date":"2022-04-29","current":-9.373083,"twenty":-3905.422542,"median":-2416.901458,"eighty":-9.234954,"marketCap":120819043},{"date":"2022-05-06","current":-17.956854,"twenty":-3677.562083,"median":-870.079052,"eighty":-9.234954,"marketCap":231463850},{"date":"2022-05-13","current":-15.163214,"twenty":-3640.4685,"median":-14.858803,"eighty":-9.323751,"marketCap":239730416},{"date":"2022-05-20","current":-12.468425,"twenty":-3608.674042,"median":-15.011008,"eighty":-9.373083,"marketCap":197125807},{"date":"2022-05-27","current":-12.597132,"twenty":-3576.879542,"median":-14.366844,"eighty":-9.373083,"marketCap":199160654},{"date":"2022-06-03","current":-9.773637,"twenty":-3517.529842,"median":-13.793232,"eighty":-9.396762,"marketCap":154521197},{"date":"2022-06-10","current":-9.652975,"twenty":-3451.82125,"median":-12.774103,"eighty":-9.410576,"marketCap":152613528},{"date":"2022-06-17","current":-8.824428,"twenty":-3383.992992,"median":-12.70975,"eighty":-9.363217,"marketCap":139514200},{"date":"2022-06-24","current":-9.242723,"twenty":-3363.856475,"median":-12.468425,"eighty":-9.239615,"marketCap":146127453},{"date":"2022-07-01","current":-9.64493,"twenty":-3353.258333,"median":-11.474627,"eighty":-9.239615,"marketCap":152486350},{"date":"2022-07-08","current":-10.224109,"twenty":-3315.104967,"median":-10.465433,"eighty":-9.275134,"marketCap":161643161},{"date":"2022-07-15","current":-9.086265,"twenty":-3249.396358,"median":-10.409124,"eighty":-9.258683,"marketCap":143653842},{"date":"2022-07-22","current":-9.586449,"twenty":-3214.422408,"median":-10.216065,"eighty":-9.238062,"marketCap":151561766},{"date":"2022-07-29","current":-7.078848,"twenty":-3195.345708,"median":-9.9848,"eighty":-9.113213,"marketCap":111916587},{"date":"2022-08-05","current":-8.052111,"twenty":-3195.345708,"median":-9.910387,"eighty":-8.975658,"marketCap":108228426},{"date":"2022-08-12","current":-9.488582,"twenty":-3159.311958,"median":-9.805813,"eighty":-8.932791,"marketCap":127536026},{"date":"2022-08-19","current":-9.793611,"twenty":-3043.792,"median":-9.810606,"eighty":-8.975658,"marketCap":131635922},{"date":"2022-08-26","current":-9.510369,"twenty":-2917.673883,"median":-9.781681,"eighty":-9.015878,"marketCap":127828876},{"date":"2022-09-02","current":-9.031038,"twenty":-2686.842208,"median":-9.757814,"eighty":-8.975658,"marketCap":121386184},{"date":"2022-09-09","current":-9.150871,"twenty":-2416.901458,"median":-9.745482,"eighty":-8.964396,"marketCap":122996857},{"date":"2022-09-16","current":-8.932993,"twenty":-2277.961416,"median":-9.701239,"eighty":-8.937021,"marketCap":120068360},{"date":"2022-09-23","current":-8.573495,"twenty":-1381.352371,"median":-9.632337,"eighty":-8.826532,"marketCap":115236341},{"date":"2022-09-30","current":-7.723771,"twenty":-17.65393,"median":-9.586518,"eighty":-8.651931,"marketCap":103815204},{"date":"2022-10-07","current":-7.63662,"twenty":-16.210562,"median":-9.563205,"eighty":-8.405729,"marketCap":102643805},{"date":"2022-10-14","current":-7.603938,"twenty":-15.261352,"median":-9.524268,"eighty":-8.26218,"marketCap":102204531},{"date":"2022-10-21","current":-7.680195,"twenty":-15.169649,"median":-9.483135,"eighty":-8.073594,"marketCap":103229505},{"date":"2022-10-28","current":-7.810268,"twenty":-15.102332,"median":-9.471747,"eighty":-7.885,"marketCap":104977817},{"date":"2022-11-04","current":-7.576703,"twenty":-14.768455,"median":-9.451943,"eighty":-7.747738,"marketCap":101838469},{"date":"2022-11-11","current":-6.796511,"twenty":-14.399021,"median":-9.402682,"eighty":-7.680195,"marketCap":99568884},{"date":"2022-11-18","current":-7.224291,"twenty":-14.29948,"median":-9.348417,"eighty":-7.640977,"marketCap":105835867},{"date":"2022-11-25","current":-7.26627,"twenty":-14.030026,"median":-9.293004,"eighty":-7.625726,"marketCap":106450851},{"date":"2022-12-02","current":-7.506147,"twenty":-13.793232,"median":-9.25981,"eighty":-7.576703,"marketCap":109965047},{"date":"2022-12-09","current":-7.506147,"twenty":-12.999339,"median":-9.210288,"eighty":-7.516141,"marketCap":109965047},{"date":"2022-12-16","current":-7.406198,"twenty":-12.782147,"median":-9.150762,"eighty":-7.496152,"marketCap":108500799},{"date":"2022-12-23","current":-7.738527,"twenty":-12.766059,"median":-9.1187,"eighty":-7.454973,"marketCap":113369424},{"date":"2022-12-30","current":-7.496152,"twenty":-12.766059,"median":-9.099176,"eighty":-7.44634,"marketCap":109818622},{"date":"2023-01-06","current":-7.594801,"twenty":-12.732274,"median":-9.091333,"eighty":-7.450405,"marketCap":111263835},{"date":"2023-01-13","current":-7.406198,"twenty":-12.642179,"median":-9.041932,"eighty":-7.450257,"marketCap":108500799},{"date":"2023-01-20","current":-7.496152,"twenty":-12.545649,"median":-9.025531,"eighty":-7.451274,"marketCap":109818622},{"date":"2023-01-27","current":-7.975905,"twenty":-12.317195,"median":-8.981288,"eighty":-7.451274,"marketCap":116847014},{"date":"2023-02-03","current":-10.369677,"twenty":-11.855901,"median":-9.025531,"eighty":-7.452843,"marketCap":151915761},{"date":"2023-02-10","current":-14.362627,"twenty":-11.979785,"median":-9.058273,"eighty":-7.455453,"marketCap":210412480},{"date":"2023-02-17","current":-9.964884,"twenty":-11.831926,"median":-9.096402,"eighty":-7.46125,"marketCap":145985555},{"date":"2023-02-24","current":-10.434643,"twenty":-11.751993,"median":-9.101951,"eighty":-7.472325,"marketCap":152867522},{"date":"2023-03-03","current":-11.973853,"twenty":-11.789947,"median":-9.134127,"eighty":-7.486157,"marketCap":175416946},{"date":"2023-03-10","current":-8.326972,"twenty":-11.789947,"median":-9.107295,"eighty":-7.488136,"marketCap":158920261},{"date":"2023-03-17","current":-9.237161,"twenty":-11.658015,"median":-9.099176,"eighty":-7.496072,"marketCap":176291215},{"date":"2023-03-24","current":-9.086429,"twenty":-11.512116,"median":-9.107295,"eighty":-7.496152,"marketCap":173414497},{"date":"2023-03-31","current":-10.133823,"twenty":-11.492386,"median":-9.134127,"eighty":-7.496152,"marketCap":193404003},{"date":"2023-04-06","current":-9.75506,"twenty":-11.456868,"median":-9.150762,"eighty":-7.496152,"marketCap":186175325},{"date":"2023-04-14","current":-11.478815,"twenty":-11.451785,"median":-9.210288,"eighty":-7.496152,"marketCap":219073184},{"date":"2023-04-21","current":-10.705831,"twenty":-11.440849,"median":-9.236058,"eighty":-7.496152,"marketCap":204320781},{"date":"2023-04-28","current":-11.463355,"twenty":-11.463355,"median":-9.251266,"eighty":-7.496152,"marketCap":218778136},{"date":"2023-05-01","current":-12.211645,"twenty":-11.469477,"median":-9.25981,"eighty":-7.496152,"marketCap":233059240},{"date":"2023-05-12","current":-11.89369,"twenty":-11.658015,"median":-9.26808,"eighty":-7.496152,"marketCap":240145501},{"date":"2023-05-19","current":-13.141553,"twenty":-11.893853,"median":-9.303385,"eighty":-7.4981,"marketCap":265341095},{"date":"2023-05-26","current":-13.572736,"twenty":-12.376667,"median":-9.373083,"eighty":-7.505944,"marketCap":274047116},{"date":"2023-06-02","current":-13.905712,"twenty":-12.463106,"median":-9.391925,"eighty":-7.506147,"marketCap":280770234},{"date":"2023-06-09","current":-13.897784,"twenty":-12.70975,"median":-9.412549,"eighty":-7.506147,"marketCap":280610160},{"date":"2023-06-16","current":-14.42896,"twenty":-12.999339,"median":-9.452014,"eighty":-7.506147,"marketCap":291335135},{"date":"2023-06-23","current":-14.056344,"twenty":-13.239822,"median":-9.471747,"eighty":-7.514142,"marketCap":283811645},{"date":"2023-06-30","current":-12.954352,"twenty":-13.244502,"median":-9.481102,"eighty":-7.534132,"marketCap":261561324},{"date":"2023-07-07","current":-12.034704,"twenty":-13.213305,"median":-9.499475,"eighty":-7.55812,"marketCap":242992711},{"date":"2023-07-14","current":-12.082272,"twenty":-13.164951,"median":-9.548401,"eighty":-7.576348,"marketCap":243953157},{"date":"2023-07-21","current":-11.321184,"twenty":-13.104727,"median":-9.564908,"eighty":-7.580464,"marketCap":228586029},{"date":"2023-07-28","current":-11.154696,"twenty":-13.046317,"median":-9.586518,"eighty":-7.586105,"marketCap":225224469},{"date":"2023-08-04","current":-11.4956,"twenty":-13.024672,"median":-9.61481,"eighty":-7.589583,"marketCap":232107662},{"date":"2023-08-11","current":-11.568146,"twenty":-12.981344,"median":-9.64493,"eighty":-7.595321,"marketCap":258316695},{"date":"2023-08-18","current":-11.190253,"twenty":-12.938496,"median":-9.709283,"eighty":-7.5961,"marketCap":249878349},{"date":"2023-08-25","current":-11.167117,"twenty":-12.914712,"median":-9.749504,"eighty":-7.599235,"marketCap":249361716},{"date":"2023-09-01","current":-11.036011,"twenty":-12.870315,"median":-9.760327,"eighty":-7.612653,"marketCap":246434127},{"date":"2023-09-08","current":-11.151692,"twenty":-12.799405,"median":-9.777659,"eighty":-7.625726,"marketCap":249017293},{"date":"2023-09-15","current":-10.81236,"twenty":-12.778929,"median":-9.805813,"eighty":-7.625726,"marketCap":241440004},{"date":"2023-09-22","current":-10.550149,"twenty":-12.766059,"median":-9.8581,"eighty":-7.627797,"marketCap":235584825},{"date":"2023-09-29","current":-10.642694,"twenty":-12.754797,"median":-9.91491,"eighty":-7.636188,"marketCap":237651359},{"date":"2023-10-06","current":-8.38305,"twenty":-12.687226,"median":-9.900583,"eighty":-7.63662,"marketCap":187193498},{"date":"2023-10-13","current":-7.380477,"twenty":-12.582954,"median":-9.815398,"eighty":-7.63662,"marketCap":164806051},{"date":"2023-10-20","current":-6.994872,"twenty":-12.517778,"median":-9.787646,"eighty":-7.625726,"marketCap":156195494},{"date":"2023-10-27","current":-6.856054,"twenty":-12.500855,"median":-9.777659,"eighty":-7.617011,"marketCap":153095694},{"date":"2023-11-03","current":-7.295644,"twenty":-12.474627,"median":-9.75506,"eighty":-7.591323,"marketCap":162911728},{"date":"2023-11-10","current":-6.384789,"twenty":-12.465234,"median":-9.745482,"eighty":-7.564117,"marketCap":142597868},{"date":"2023-11-17","current":-6.361515,"twenty":-12.460749,"median":-9.701239,"eighty":-7.506147,"marketCap":142078070},{"date":"2023-11-24","current":-6.361515,"twenty":-12.450927,"median":-9.64493,"eighty":-7.496152,"marketCap":142078070},{"date":"2023-12-01","current":-6.594253,"twenty":-12.430299,"median":-9.61481,"eighty":-7.496152,"marketCap":147276049},{"date":"2023-12-08","current":-6.547705,"twenty":-12.335412,"median":-9.586518,"eighty":-7.486157,"marketCap":146236453},{"date":"2023-12-15","current":-6.625285,"twenty":-12.194779,"median":-9.564908,"eighty":-7.452843,"marketCap":147969112},{"date":"2023-12-22","current":-6.260661,"twenty":-12.140939,"median":-9.548401,"eighty":-7.432254,"marketCap":139825613},{"date":"2023-12-29","current":-6.648559,"twenty":-12.098128,"median":-9.517319,"eighty":-7.416193,"marketCap":148488910},{"date":"2024-01-05","current":-6.4934,"twenty":-12.093462,"median":-9.488582,"eighty":-7.408281,"marketCap":145023591},{"date":"2024-01-12","current":-7.54848,"twenty":-12.085504,"median":-9.474718,"eighty":-7.408281,"marketCap":168587759},{"date":"2024-01-19","current":-6.439094,"twenty":-12.082272,"median":-9.46188,"eighty":-7.391646,"marketCap":143810730},{"date":"2024-01-26","current":-5.996891,"twenty":-12.063245,"median":-9.451871,"eighty":-7.358883,"marketCap":133934571},{"date":"2024-02-02","current":-5.539173,"twenty":-12.010364,"median":-9.403927,"eighty":-7.324002,"marketCap":123711881},{"date":"2024-02-09","current":-5.345224,"twenty":-11.96331,"median":-9.373083,"eighty":-7.303747,"marketCap":119380232},{"date":"2024-02-16","current":-6.105503,"twenty":-11.93164,"median":-9.313568,"eighty":-7.27802,"marketCap":136360294},{"date":"2024-02-23","current":-5.787427,"twenty":-11.905064,"median":-9.279216,"eighty":-7.226222,"marketCap":129256391},{"date":"2024-03-01","current":-7.657092,"twenty":-11.893853,"median":-9.25981,"eighty":-7.201903,"marketCap":171013482},{"date":"2024-03-08","current":-8.110119,"twenty":-11.888595,"median":-9.239942,"eighty":-7.226222,"marketCap":180531251},{"date":"2024-03-15","current":-7.303897,"twenty":-11.863459,"median":-9.185622,"eighty":-7.234415,"marketCap":162584739},{"date":"2024-03-22","current":-7.224073,"twenty":-11.84433,"median":-9.144455,"eighty":-7.224117,"marketCap":160807857},{"date":"2024-03-28","current":-6.657322,"twenty":-11.84392,"median":-9.1187,"eighty":-7.196306,"marketCap":148191992},{"date":"2024-04-05","current":-6.154431,"twenty":-11.813935,"median":-9.096402,"eighty":-7.141402,"marketCap":136997633},{"date":"2024-04-12","current":-5.922941,"twenty":-11.807221,"median":-9.086347,"eighty":-7.106352,"marketCap":131844674},{"date":"2024-04-19","current":-5.364173,"twenty":-11.73344,"median":-9.082564,"eighty":-7.087417,"marketCap":119406497},{"date":"2024-04-26","current":-5.196543,"twenty":-11.725512,"median":-9.036485,"eighty":-7.056377,"marketCap":115675044},{"date":"2024-05-03","current":-5.5789,"twenty":-11.693997,"median":-9.020144,"eighty":-6.994872,"marketCap":124186324},{"date":"2024-05-10","current":-5.232404,"twenty":-11.670016,"median":-8.943064,"eighty":-6.926009,"marketCap":117111662},{"date":"2024-05-17","current":-5.355423,"twenty":-11.568146,"median":-8.86763,"eighty":-6.867017,"marketCap":119865071},{"date":"2024-05-24","current":-5.478442,"twenty":-11.551096,"median":-8.824241,"eighty":-6.807818,"marketCap":122618480},{"date":"2024-05-31","current":-5.248806,"twenty":-11.540057,"median":-8.78056,"eighty":-6.750346,"marketCap":117478784},{"date":"2024-06-07","current":-5.355423,"twenty":-11.535651,"median":-8.71467,"eighty":-6.643904,"marketCap":119865071},{"date":"2024-06-14","current":-5.601461,"twenty":-11.522593,"median":-8.700328,"eighty":-6.585481,"marketCap":125371889},{"date":"2024-06-21","current":-5.601461,"twenty":-11.514132,"median":-8.595282,"eighty":-6.550808,"marketCap":125371889},{"date":"2024-06-28","current":-5.14219,"twenty":-11.514103,"median":-8.591276,"eighty":-6.544445,"marketCap":115092496},{"date":"2024-07-05","current":-5.084781,"twenty":-11.509505,"median":-8.549205,"eighty":-6.524432,"marketCap":113807572},{"date":"2024-07-12","current":-5.248806,"twenty":-11.505115,"median":-8.477607,"eighty":-6.501158,"marketCap":117478784},{"date":"2024-07-15","current":-5.396429,"twenty":-11.504671,"median":-8.471907,"eighty":-6.499606,"marketCap":120782874},{"date":"2024-08-02","current":-5.068379,"twenty":-11.504226,"median":-8.439046,"eighty":-6.4934,"marketCap":113440450},{"date":"2024-08-09","current":-6.04608,"twenty":-11.4956,"median":-8.380128,"eighty":-6.446852,"marketCap":127584385},{"date":"2024-08-16","current":-5.568758,"twenty":-11.4956,"median":-8.33936,"eighty":-6.431336,"marketCap":117511934},{"date":"2024-08-23","current":-6.364295,"twenty":-11.487672,"median":-8.317646,"eighty":-6.400304,"marketCap":134299353},{"date":"2024-08-30","current":-6.001884,"twenty":-11.478815,"median":-8.282792,"eighty":-6.361515,"marketCap":126651751},{"date":"2024-09-06","current":-5.445008,"twenty":-11.472569,"median":-8.234715,"eighty":-6.361515,"marketCap":114900558},{"date":"2024-09-13","current":-5.745544,"twenty":-11.464886,"median":-8.172852,"eighty":-6.350611,"marketCap":121242472},{"date":"2024-09-20","current":-5.966527,"twenty":-11.457439,"median":-8.106128,"eighty":-6.299451,"marketCap":125905644},{"date":"2024-09-27","current":-5.445008,"twenty":-11.447214,"median":-8.0288,"eighty":-6.249174,"marketCap":114900558},{"date":"2024-10-04","current":-5.445008,"twenty":-11.428314,"median":-7.993998,"eighty":-6.196292,"marketCap":114900558},{"date":"2024-10-11","current":-5.471526,"twenty":-11.41595,"median":-7.975905,"eighty":-6.137667,"marketCap":115460138},{"date":"2024-10-18","current":-5.975366,"twenty":-11.389225,"median":-7.92057,"eighty":-6.076134,"marketCap":126092170},{"date":"2024-10-25","current":-7.734386,"twenty":-11.342169,"median":-7.870838,"eighty":-6.088277,"marketCap":163211020},{"date":"2024-10-31","current":-6.974207,"twenty":-11.32549,"median":-7.854682,"eighty":-6.099297,"marketCap":147169708},{"date":"2024-11-08","current":-8.029494,"twenty":-11.299815,"median":-7.828418,"eighty":-6.086567,"marketCap":155563417},{"date":"2024-11-15","current":-5.516667,"twenty":-11.283906,"median":-7.854682,"eighty":-6.086567,"marketCap":106879902},{"date":"2024-11-22","current":-4.886589,"twenty":-11.259662,"median":-7.803133,"eighty":-6.007187,"marketCap":94672767},{"date":"2024-11-29","current":-5.026205,"twenty":-11.229851,"median":-7.772793,"eighty":-5.982437,"marketCap":97377703},{"date":"2024-12-06","current":-4.746972,"twenty":-11.207233,"median":-7.743226,"eighty":-5.930799,"marketCap":91967831},{"date":"2024-12-13","current":-4.6273,"twenty":-11.199507,"median":-7.732114,"eighty":-5.891293,"marketCap":89649314},{"date":"2024-12-20","current":-4.677163,"twenty":-11.187168,"median":-7.695034,"eighty":-5.858687,"marketCap":90615363},{"date":"2024-12-27","current":-5.00626,"twenty":-11.179456,"median":-7.680195,"eighty":-5.833974,"marketCap":96991284},{"date":"2025-01-03","current":-5.375247,"twenty":-11.167117,"median":-7.680195,"eighty":-5.765486,"marketCap":104140044},{"date":"2025-01-10","current":-6.153113,"twenty":-11.15718,"median":-7.674115,"eighty":-5.765219,"marketCap":119210403},{"date":"2025-01-17","current":-5.445056,"twenty":-11.152293,"median":-7.657092,"eighty":-5.745544,"marketCap":105492512},{"date":"2025-01-24","current":-6.402428,"twenty":-11.143981,"median":-7.63662,"eighty":-5.743678,"marketCap":124040646},{"date":"2025-01-31","current":-6.721552,"twenty":-11.137297,"median":-7.62606,"eighty":-5.745544,"marketCap":130223358},{"date":"2025-02-07","current":-8.933023,"twenty":-11.094623,"median":-7.625726,"eighty":-5.756709,"marketCap":173068391},{"date":"2025-02-14","current":-8.575209,"twenty":-11.04835,"median":-7.63608,"eighty":-5.764953,"marketCap":166136094},{"date":"2025-02-21","current":-9.278499,"twenty":-11.027345,"median":-7.63662,"eighty":-5.774262,"marketCap":179761644},{"date":"2025-02-28","current":-8.442054,"twenty":-11.010673,"median":-7.657749,"eighty":-5.790095,"marketCap":160399020},{"date":"2025-03-07","current":-7.571459,"twenty":-11.00084,"median":-7.658407,"eighty":-5.794098,"marketCap":143857718},{"date":"2025-03-14","current":-10.279948,"twenty":-10.991897,"median":-7.680195,"eighty":-5.810034,"marketCap":195319016},{"date":"2025-03-21","current":-11.51108,"twenty":-11.024301,"median":-7.680195,"eighty":-5.833952,"marketCap":218710515},{"date":"2025-03-28","current":-11.880419,"twenty":-11.05452,"median":-7.709402,"eighty":-5.833974,"marketCap":225727965},{"date":"2025-04-04","current":-11.14174,"twenty":-11.147711,"median":-7.734386,"eighty":-5.837495,"marketCap":211693065},{"date":"2025-04-11","current":-10.495396,"twenty":-11.14058,"median":-7.744393,"eighty":-5.846312,"marketCap":199412528},{"date":"2025-04-17","current":-10.710844,"twenty":-11.149702,"median":-7.758662,"eighty":-5.855152,"marketCap":203506041}],"updateTime":1745005473070}}}